The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma.
作者： Tobias A. W. Holderried , Alessia Fraccaroli , Martin Schumacher , Annkristin Heine , Peter Brossart
DOI: 10.1038/S41409-019-0498-0
关键词: Stem cell 、 Internal medicine 、 Disease 、 Medicine 、 Blockade 、 Transplantation 、 Hematopoietic stem cell transplantation 、 Lymphoma 、 Donor lymphocyte infusion 、 Hodgkin's lymphoma 、 Oncology
摘要: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment option for many malignant high-risk hematological diseases. The Graft-vs.-Tumor (GvT) effect major hallmark of this approach. However, disease relapse remains a limitation. Boosting GvT by checkpoint inhibitors (CI) an attractive in desperate situation although potentially triggering Graft-vs.-Host Disease (GvHD). Early reports patients with Hodgkin's lymphoma support idea that CI therapy after HSCT feasible and effective. We have retrospectively analyzed recurrence allo-HSCT other than including 21 from eight German transplant centers. median follow-up was 59 days. overall response rate (ORR) 43%. Patients receiving donor lymphocyte infusion (DLI) combination had superior (ORR 80%). Severe acute GvHD grade III-IV moderate to severe chronic were observed 29% all patients. Taken together, relapsed HSCT, especially DLI, effective but induces considerable proportion Thus, prospective trials or EBMT registry-based validation different dosing application schedules immunosuppressive regimens those are urgently needed.
nature.com
sci-hub.se 参考文章(24)
PY Yew, H Alachkar, R Yamaguchi, K Kiyotani, H Fang, KL Yap, HT Liu, A Wickrema, A Artz, K Van Besien, S Imoto, S Miyano, MR Bishop, W Stock, Y Nakamura, None, Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation. ,vol. 50, pp. 1227- 1234 ,(2015) , 10.1038/BMT.2015.133
S Dermime, D Mavroudis, Y-Z Jiang, N Hensel, J Molldrem, AJ Barrett, Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation Bone Marrow Transplantation. ,vol. 19, pp. 989- 999 ,(1997) , 10.1038/SJ.BMT.1700778
Asad Bashey, Bridget Medina, Sue Corringham, Mildred Pasek, Ewa Carrier, Linda Vrooman, Israel Lowy, Scott R. Solomon, Lawrence E. Morris, H. Kent Holland, James R. Mason, Edwin P. Alyea, Robert J. Soiffer, Edward D. Ball, CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation Blood. ,vol. 113, pp. 1581- 1588 ,(2009) , 10.1182/BLOOD-2008-07-168468
John R. Wingard, Navneet S. Majhail, Ruta Brazauskas, Zhiwei Wang, Kathleen A. Sobocinski, David Jacobsohn, Mohamed L. Sorror, Mary M. Horowitz, Brian Bolwell, J. Douglas Rizzo, Gérard Socié, Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation Journal of Clinical Oncology. ,vol. 29, pp. 2230- 2239 ,(2011) , 10.1200/JCO.2010.33.7212
S Yanovich, E A Sausville, C Ujjani, K Ruehle, C Goecke, M Landau, A P Rapoport, J A Yared, N Hardy, Z Singh, S Hajj, A Z Badros, M Kocoglu, Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation Bone Marrow Transplantation. ,vol. 51, pp. 850- 852 ,(2016) , 10.1038/BMT.2015.346
Matthew S. Davids, Haesook T. Kim, Pavan Bachireddy, Caitlin Costello, Rebecca Liguori, Alexandra Savell, Alexander P. Lukez, David Avigan, Yi-Bin Chen, Peter McSweeney, Nicole R. LeBoeuf, Michael S. Rooney, Michaela Bowden, Chensheng W. Zhou, Scott R. Granter, Jason L. Hornick, Scott J. Rodig, Masahiro Hirakawa, Mariano Severgnini, F. Stephen Hodi, Catherine J. Wu, Vincent T. Ho, Corey Cutler, John Koreth, Edwin P. Alyea, Joseph H. Antin, Philippe Armand, Howard Streicher, Edward D. Ball, Jerome Ritz, Asad Bashey, Robert J. Soiffer, Ipilimumab for Patients with Relapse after Allogeneic Transplantation The New England Journal of Medicine. ,vol. 375, pp. 143- 153 ,(2016) , 10.1056/NEJMOA1601202
J C Albring, S Inselmann, T Sauer, C Schliemann, B Altvater, S Kailayangiri, C Rössig, W Hartmann, J R Knorrenschild, K Sohlbach, C Groth, M Lohoff, A Neubauer, W E Berdel, A Burchert, M Stelljes, PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation Bone Marrow Transplantation. ,vol. 52, pp. 317- 320 ,(2017) , 10.1038/BMT.2016.274
E McDuffee, G Aue, L Cook, C Ramos-Delgado, R Shalabi, T Worthy, P Vo, R W Childs, Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation Bone Marrow Transplantation. ,vol. 52, pp. 759- 761 ,(2017) , 10.1038/BMT.2016.346
James A. Kennedy, Benjamin L. Ebert, Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. Journal of Clinical Oncology. ,vol. 35, pp. 968- 974 ,(2017) , 10.1200/JCO.2016.71.0806
Charles Herbaux, Jordan Gauthier, Pauline Brice, Elodie Drumez, Loic Ysebaert, Hélène Doyen, Luc Fornecker, Krimo Bouabdallah, Guillaume Manson, Hervé Ghesquières, Reza Tabrizi, Eric Hermet, Julien Lazarovici, Anne Thiebaut-Bertrand, Adrien Chauchet, Hélène Demarquette, Eileen Boyle, Roch Houot, Ibrahim Yakoub-Agha, Franck Morschhauser, Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. ,vol. 129, pp. 2471- 2478 ,(2017) , 10.1182/BLOOD-2016-11-749556